Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.
The CAR T product bb2121 is for patients with relapsed or refractory multiple myeloma. In a phase I dose-escalation study, 24 patients were collected, and 21 patients were infused with the CAR T cell. Considering that this is a heavily pretreated population, Berdeja says that the number of patients infused was impressive.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
